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Background: Inflammasome-mediated activation of caspase-1 regulates inflammatory 
responses and pyroptosis. We analyzed possible associations between inflammasome- 
related genes and immune reconstitution in HIV-infected antiretroviral therapy (ART)-
treated patients.
Methods: Cross-sectional, case–control study. HIV-infected patients on ART for
≥24 months with HIV-RNA<50 cp/mL for ≥12 months were enrolled and defined as 
immunological responders (IR) or non-responders (INR) if CD4 count was ≥500 or 
≤350 cells/μL, respectively. Expression of inflammasome genes, caspases 1, 3, 4, 5 
and γ-interferon-inducible protein 16 (IFI16) was measured in unstimulated and LPS- 
or aldrithiol-2-treated HIV-1BaL virions-stimulated peripheral blood mononuclear cells. 
Microbial translocation markers were evaluated.
results: Thirty-nine patients (22 IRs; 17 INRs) were enrolled. LPS-stimulated inflam-
masome genes were significantly upregulated in INRs. Whereas HIV-1BaL stimulation 
induced (NOD)-like receptor (NLR) family pyrin domain containing 3 (NLRP3) expression 
in both IRs and INRs, NLRP3 and IL-18 expression was significantly increased in INRs 
compared to IRs. Significant higher caspase-1 expression was seen as well, whereas 
caspase 3, 4, and 5 expression was similar in both groups. No differences in microbial 
translocation markers (LPS and soluble CD14) were detected in the two groups.
conclusion: Upregulation of NLRP3 and caspase-1 is observed in INR patients. This 
could play a role in persistent immune activation that characterize INRs. Caspase-1 
upregulation could induce CD4 T-cell loss via pyroptosis, contributing to unsatisfactory 
CD4 T-cells recovery.
 
Keywords: inflammasome, caspase, pyroptosis, hiV, immune reconstitution
Summary: Higher levels of the inflammasome genes, NLRP3 and caspase-1, are observed in ART-
treated patients who lack immunological recovery. Inflammasome upregulation in immunological 
non-responders (INR) may be partly responsible for the persistence of immune activation and to 
CD4 T-cell loss via pyroptosis.
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inTrODUcTiOn
Elevated levels of inflammation and immune activation, which 
can persevere in HIV-infected individuals on virologically 
effective antiretroviral therapy (ART), have been associated to 
morbidity and mortality from non-AIDS events, such as car-
diovascular disease, neurocognitive dysfunction, and kidney and 
bone disorders (1, 2). These events are more frequently observed 
in HIV-infected patients unable to reach a CD4+ T-cell count of 
500/mm3, thus defined as INR.
Increases in immune activation (3) and inflammation (4) are 
currently believed to be the principal correlates of poor immu-
nological response to ART, affecting T-cell pool homeostasis 
and modifying T lymphocytes counts at peripheral and thymic 
levels. Peculiar host genetic factors, as polymorphisms of genes 
of the pathway relative to inflammation/apoptosis (5) or genes 
implicated in T-cell homeostasis, such as IL7R (6), have also been 
correlated to suboptimal CD4+ T-cell reconstitution.
Inflammasome activation is essential for host response to 
pathogens, but recently clear roles for the inflammasome in 
the pathogenesis of inflammatory diseases has been evidenced 
in several studies [rev. in Ref. (7)]. The nucleotide-binding 
oligomerization domain (NOD)-like receptor (NLR) family, 
pyrin domain containing 3 (NLRP3) inflammasome is the 
prevalently studied among inflammasomes. Upon inflamma-
some activation, the NLRP3 protein recruits the inflamma-
some adaptor protein apoptosis-associated speck-like protein 
(ASC), which contains a C-terminal caspase recruitment 
domain, which interacts with pro-caspase-1 inducing its 
cleavage and activation. Inflammasome-dependent caspase-1 
activity results in a specific inflammatory form of cell death 
known as pyroptosis, where dying cells release their cyto-
plasmic contents, including inflammatory cytokines, into the 
extracellular space (8, 9). Molecular mechanisms of chronic 
inflammation observed in HIV-infected patients successfully 
treated with ART are not clear. Recently, pyroptosis has been 
implicated in CD4 +  T-cell loss even in absence of ongoing 
productive HIV replication (10–14).
As the role of the inflammasome system in the lack of immune 
reconstitution during ART has not been investigated till now, we 
analyzed possible associations between inflammasome activity, 
caspase-1 activation, pyroptosis, and immune reconstitution 
in HIV-infected ART-treated patients. Specifically, we assessed 
the expression of NLRP3 inflammasome, caspases 1, 3, 4, 5, and 
pro-inflammatory cytokines in peripheral blood mononuclear 
cells (PBMCs) of HIV-infected patients under suppressive 
ART and investigated their association with CD4+ T-cell count 
reconstitution.
MaTerials anD MeThODs
study Design
Cross-sectional, case–control study in which 39 HIV-infected 
ART-treated patients have been enrolled at the Unit of Infectious 
Diseases, San Gerardo Hospital, Monza, Italy. Patients identi-
fied as cases were HIV-infected patients defined as INR; 
controls were HIV-infected patients defined as immunological 
responders (IRs).
Inclusion criteria were: men and women >18  years of age, 
HIV positivity tested with ELISA and confirmed by Western Blot, 
treatment with combined ART (i.e., >3 antiretroviral drugs), 
duration of ART > 24 months, plasma HIV-RNA < 50 cp/mL for 
at least 12 months, CD4 + T lymphocyte count<350/mmc if INR, 
CD4 + T lymphocyte count >500/mmc if IRs, informed consent 
signed. Immunological response to ART was considered optimal 
when CD4+ T-cell counts were above 500 cells/mmc as these 
levels of immune reconstitution are associated with morbidity 
and mortality rates close to uninfected individuals (15).
Exclusion criteria were as follows: presence of actual oppor-
tunistic AIDS-related diseases, HCV chronic infection, chronic 
inflammatory disorders, and ongoing immunosuppressive therapy.
This study was conducted in accordance with the recommen-
dations of the Ethical Committee of our Institution (Comitato 
Etico Brianza, Italy) including written informed consent from 
all patients. All subjects provided written informed consent 
in accordance with the Declaration of Helsinki. The protocol 
was approved by the Ethical Committee of Brianza on 29th 
May 2014.
Blood sample collection and Peripheral 
Blood Mononuclear cell separation
Whole blood was collected by venipuncture in Vacutainer tubes 
containing EDTA (Becton Dickinson, Rutherford, NJ, USA). 
Plasma was stored at −80°C for further analysis and PBMCs 
were separated on lymphocyte separation medium (Cedarlane 
laboratories Limited, Hornby, ON, Canada) and washed twice 
in phosphate-buffered saline (PBI, Milan, Italy). Number of 
viable leukocytes was determined by automated cell counter 
ADAM-MC (Digital Bio, NanoEnTek Inc., Korea).
stimulation of PBMcs
Peripheral blood mononuclear cells were cultured in RPMI 
medium supplemented with 1% l-glutamine (Sigma-Aldrich, 
Milan, Italy), 1% penicillin/streptomycin (Sigma-Aldrich, Milan, 
Italy), and 10% Human AB Serum (Euroclone, Milan, Italy). 
PBMCs were incubated for 3 h either in absence or in presence of 
LPS (1 µg/ml) (Sigma-Aldrich, Milan, Italy) and for 24 h either 
in absence or in presence of aldrithiol-2 (AT2 treated)- HIV-1BaL 
virions (300 ng/ml).
inflammasome Pathway evaluation  
by qrT-Pcr array
Analyses were performed both in basal and stimulated condi-
tions. mRNA was extracted from 1 × 106 PBMCs by using the 
acid guanidinium thiocyanate–phenol–chloroform method, dis-
solved in RNase-free water, and purified from genomic DNA with 
RNase-free DNase (New England BioLabs, Ipswich, MA, USA). 
One microgram of RNA was reverse-transcribed into first-strand 
cDNA in a 20-µl final volume containing 1 µM random hexanu-
cleotide primers, 1 µM oligo (dT), and 200 U of Moloney murine 
leukemia virus reverse transcriptase (Promega, Madison, WI, 
USA). Inflammasome signaling pathways were analyzed by a PCR 
TaBle 1 | Clinical and demographic characteristics of HIV-infected patients 
enrolled in the study.
immunological 
responder (n = 22)
immunological non-
responders (n = 17)
p
Age 43 (40–48) 60 (50–66) <0.001
Male gender 16 (72.7) 14 (82.4) ns
Caucasian 19 (86.4) 14 (82.4) ns
Risk factor ns
Heterosexual 11 (50) 10 (58.8)
Homosexual 5 (22.7) 4 (23.5)
Unknown 6 (27.3) 3 (17.6)
Years from HIV 
diagnosis
9.3 (6.2–20.2) 10.2 (3.8–15.6) ns
Past AIDS-defining 
events
4 (18.2) 13 (76.5) <0.001
CD4 nadir 196 (85–298) 44(25–83) <0.01
CD4 840 (718–1131) 295 (256–343) <0.001
CD4% 34 (28–40) 19 (16–21) <0.001
CD8 1139 (781–1383) 685 (489–899) 0.001
CD8% 41 (36–47) 48 (37–53) ns
CD4/CD8 0.81 (0.60–1.03) 0.41 (0.29–0.58) <0.001
CD4/CD8 > 1 6 (27.3) 0 0.027
Months from last 
VL > 50
53.7 (33.4–67.7) 59 (25.9–84.9) ns
Years from cART 
initiation
7.7 (4.8–11.2) 10.2 (3.3–13.4) ns
Months from last 
regimen initiation
48.5 (18.2–60.9) 16.8 (5.5–41.2) ns
NRTI 20 (90.9) 16 (94.1) ns
NNRTI 12 (54.5) 7 (41.2) ns
PI 6 (27.3) 6 (35.3) ns
InSTI 6 (27.3) 7 (41.2) ns
EI 0 0 ns
Median and interquartile ranges are shown.
VL, viral load. cART, combinational antiretroviral therapy.
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array including a set of 84 optimized real-time PCR primer assays 
on 96-well plates (SABiosciences Corporation, Frederick, MD, 
USA) according to manufacturer’s instructions. The experiments 
have been run on samples pooled into two distinct groups (INRs 
and IRs) on the basis of condition (unstimulated, LPS-stimulated 
and AT2-treated HIV-1BaL stimulated) and represent the mean 
value of the different targets analyzed in each group. The results 
were calculated relative to the housekeeping genes GAPDH and 
β-actin. Data were analyzed by SABioscences online software and 
only variables with at least a twofold increase in their value are 
presented, as previously described (16, 17).
gene expression analysis by qrT-Pcr
For Real-Time PCR (96 CFX Connect Bio-Rad) experiments, 
reactions were performed using a SYBR Green PCR mix (iTaq™ 
Universal SYBR Green Supermix, Bio-Rad). GAPDH and β-Actin 
were used as housekeeping genes and the mean Ct of these two 
genes was used as housekeeping gene. Results are expressed as 
fold change 2^ΔΔCt and were calculated according to Livak’s 
method (18). Primers sequences were the following: GAPDH 
primers: forward CGGATTTGGTCGTATTGGG, reverse GCT 
TCCCGTTCTCAGCCTTG; β-actin primers: forward ATGCCCA 
GGAAGGAAGGCTG, reverse GGGAAATCGTGCGTGACATT; 
IL-1β primers: forward TTCTGCTTGAGAGGTGCTGATG, 
reverse TGTCCTGCGTGTTGAAAGATGA; IL-18 primers: for 
ward GCTGCTGAACCAGTAGAAGAC, reverse CCGATTTC 
CTTGGTCAATGAAGA. For detection of NLRP3, Caspase-1, 
Caspase-3, Caspase-4, Caspase-5 and γ-interferon-inducible 
protein 16 (IFI16) primers were purchased already optimized 
(PrimePCR, Bio-Rad, Segrate, Italy).
Plasma caspase-1 concentration
Caspase-1 was measured by Quantikine ELISA Kit (R&D 
Systems; Minneapolis, MN, USA) according to manufacturer’s 
instructions. Plasma samples were diluted 1:2 prior to assay.
Microbial Translocation evaluation
LPS was measured by Limulus Amebocyte Lysate (LAL) 
Chromogenic Endpoint Assay (Hycult Biotechnology, Uden, The 
Netherlands). Samples, standards, and reagents were prepared 
according to manufacturer’s instructions. Plasma samples were 
heated at 75°C for 5 min in order to neutralize endotoxin inhibit-
ing compounds and diluted 1:5 in endotoxin free water prior 
to assay. Soluble CD14 (sCD14) was measured by Quantikine 
ELISA Kit (R&D Systems, Minneapolis, MN, USA), following 
manufacturer’s instructions; plasma samples were diluted 1:400 
prior to assay.
statistical analysis
This is a pilot study without sample size computation. Potential 
differences of inflammasome activation between the two groups 
(INR vs IR) have been evaluated.
Descriptive results have been presented as mean ± SE upon 
description of data distribution (median, percentiles, minimum, 
maximum), medians with interquartile range (IQR). Inferential 
statistics using either parametric (unpaired Student’s t-test) or 
non-parametric tests (Mann–Whitney t-test) have been used, as 
appropriate. Sample distributions were assessed by KS normality 
test. Variables associated with inflammasome gene expression 
were also evaluated by univariate and multivariate linear regres-
sion analysis. Data were analyzed by GraphPad Prism analysis 
software.
resUlTs
study Population
Thirty-nine HIV-infected patients, 17 INRs and 22 IRs, were 
enrolled in the study. Demographic characteristics of patients are 
shown in Table 1. Median age was 47 years, time of HIV infection 
diagnosis 10 years, time with HIV-RNA<50 cp/mL 57 months. 
INR patients were older (median 60 vs 43 years, p < 0.001) and, 
as expected, had a higher prevalence of past AIDS-defining 
illnesses (76 vs 18%, p <  0.001). Nadir CD4 T-cell count was 
significantly lower in INRs as compared to IRs [median 44 (IQR 
25–83) cells/μL vs 196 (IQR 85–298) cells/μL, p < 0.01] Median 
CD4 count was 295 (IQR 256–343) cells/μL in INRs vs 840 (IQR 
718–1131) cells/μL in IRs, median CD4 percentage was 19% (IQR 
16–21) in INRs, and 34% (IQR 28–40) in IRs. No significant dif-
ferences were observed between the two groups when years from 
HIV diagnosis, duration of HIV-RNA suppression, years from 
ART initiation and current regimen of AR were analyzed.
FigUre 1 | Inflammasome pathway. Real-time PCR Array on LPS- or AT2-treated-HIV-1BaL-stimulated peripheral blood mononuclear cells (PBMCs) in INR and IR 
HIV-infected patients. Samples were pooled into two distinct groups (IRs and INRs) and experiment was done in triplicate. Gene expression (nfold) is shown as a 
color scale from green to red (MEV multiple experiment viewer software). (a) Nfold LPS-stimulated PBMCs vs unstimulated PBMCs; (B) Nfold AT2-treated-HIV-1BaL 
PBMCs vs unstimulated PBMCs. Only targets showing at least >2-fold modulation are shown in table.
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Modulation of the expression  
of inflammasome genes
To evaluate the expression of the inflammasome pathway, we per-
formed a real-time PCR Array on PBMCs that were unstimulated 
or stimulated with either LPS or AT2-treated HIV-1BaL; samples 
were pooled into two distinct groups IRs and INRs (Figure 1). 
LPS is an activator of inflammasome response, whereas stimula-
tion with AT2-treated HIV was performed in order to evaluate 
if the virus can potentially trigger an inflammasome response 
even in the context of chronic and unproductive HIV infection. 
Upon LPS stimulation, INRs showed an upregulation (nfold 
LPS-stimulated vs unstimulated >2) of many targets, including 
caspase-1, IL-1β, IL-18, NLRP3, and other pro-inflammatory 
cytokines, such as TNF and IL-6 and kinases involved in cellular 
death pathways such as RIPK1 and RIPK2 compared to IRs. AT2-
HIV1-BaL stimulation was less potent in triggering inflammasome 
responses, but we could still detect an upregulation (nfold AT2-
HIV-1 stimulation vs unstimulated >2) for caspase-1 both in 
IRs and INRs, which is interesting considering its pivotal role in 
pyroptotic cell death and inflammation.
increased inflammasome and Pyroptosis 
gene expression in inrs
Given the results of the qRT-PCR array analysis, we further char-
acterized the expression of inflammasome genes in each subject 
included in the study either in unstimulated or in LPS- or AT2-
HIV-1BaL-stimulated PBMCs. In particular NLRP3, IL1β, IL-18, 
CASPASE-1, and IFI16 gene expression was evaluated (Figure 2). 
Upon LPS stimulation, we observed a significant increase of IL-1β 
(p <  0.05), IL-18, and caspase-1 (p <  0.02) in INRs compared 
to IRs. Upon AT2-HIV-1BaL stimulation, we observed significant 
increases of NLRP3 (p < 0.05), IL-18 (p < 0.02) and caspase-1 
(p <  0.02) in INRs compared to IRs. Of note, NLRP3 expres-
sion was significantly higher (p =  0.02) in INRs compared to 
IRs in unstimulated cells and this association was confirmed 
also after adjustment for either age (mean change +2.052, 95% 
FigUre 2 | Inflammasome and pyroptosis gene expression. NLRP3, IL1β, IL-18, Caspase-1, and γ-interferon-inducible protein 16 (IFI16) expressions were 
quantified in peripheral blood mononuclear cells (PBMCs) from each patient enrolled in the study (n = 22 for IRs and n = 17 for INRs) either unstimulated or  
LPS or AT2-treated-HIV-1BaL stimulated. White bars represent IRs, gray bars represent INRs. Mean values and SEM are shown. *p < 0.05; **p < 0.02.  
Fold change expressed as 2ΔΔCt.
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CI 0.208–3.896, p = 0.03) or CD4 + T-cell nadir (mean change 
2.222, 95% CI 0.277–4.167, p =  0.027). Altogether these data 
point out that a higher degree of inflammasome activation is 
seen in INRs compared to IRs. Of note, the gene expression of 
caspase-1, which is the key effector molecule of inflammasome 
pathway and pyroptotic cell death, was significantly higher in 
INRs in each condition analyzed. This association was confirmed 
after adjustment for CD4 + T-cells nadir value (p = 0.039, mean 
change  =  15.850, 95% CI 0.860–30.839 for LPS stimulation; 
p = 0.032, mean change = 6.785, 95% CI 0.612–12.958 for AT2-
stimulation) but not after adjustment for age. Expression levels of 
IFI16 were similar in both groups analyzed.
caspase-4 and -5 are not involved  
in nlrP3 Modulation in inrs
NLRP3 expression can be modulated also via a “non-canonical 
pathway,” which is mediated by caspase-4 and caspase-5. Therefore, 
we decided to evaluate caspase-4 and caspase-5 gene expression 
in INRs and IRs as well. Results showed that the expression of 
these caspases was comparable in both groups of patients, indicat-
ing that the “non-canonical” pathway is not involved in NLRP3 
upregulation in these patients and in the context of suppressed 
viremia (Figure 3).
apoptotic caspase-3 gene expression  
in inrs and irs
Caspase-3 is associated with apoptosis, a form of programmed 
cell death that does not lead to inflammation. We observed no 
significant differences between the two groups in any of the con-
ditions analyzed (Figure 3), suggesting that caspase-3-mediated 
apoptosis may be similar in INRs and IRs.
Plasma caspase-1 expression  
in inrs and irs
We further investigated caspase-1 expression in plasma of INRs 
and IRs. Results indicated that higher median levels of caspase-1 
expression were observed in INRs compares to IRs (INRs: 526.7 
vs IRs: 375.3  pg/ml); these differences approached but did not 
reach statistical significance (data not shown).
inflammasome Upregulation is not 
Mediated by Microbial Translocation
Microbial translocation has been suggested to be the main driver 
of immune activation in HIV-infected patients. We hypothesized 
that increased expression of some inflammasomes-related genes 
observed in INRs could be due to increased levels of microbial 
translocation. To this end, we analyzed plasma levels of sCD14 
and LPS, two of the main hallmarks of microbial translocation. 
Unexpectedly, we could not detect any differences between the 
two groups of patients (data not shown, sCD14 median levels: 
IRs 1,626,000 vs INRs 1,723,000 pg/ml; LPS median levels: IRs 
46.24 vs 47.87 EU/ml), indicating that microbial translocation 
is not the main driver of inflammasome upregulation in INRs 
and that, probably, does also not play a pivotal role in immune 
activation in ART-treated patients.
FigUre 3 | Caspase 3, 4, and 5 gene expression. Caspase 3, 4 and 5 expressions were quantified in peripheral blood mononuclear cells (PBMCs) from each 
patient enrolled in the study (n = 22 for immunological responders (IRs) and n = 17 for INRs) either unstimulated or LPS or AT2-treated-HIV-1BaL stimulated. Mean 
values and SEM are shown. White bars represent IRs, gray bars represent INRs. Fold change expressed as 2ΔΔCt.
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DiscUssiOn
Our study provides insight into one of the major mechanisms 
involved in the lack of immune recovery in HIV-infected sub-
jects experiencing virological suppression under ART regimens. 
Differently from other studies analyzing poor immune recovery, 
we applied strict patients’ selection criteria, and most of the 
characteristics influencing immune recovery that emerged from 
previous studies were considered in our population (age, sex, 
durations of infection and treatment, co-infections, duration of 
HIV-RNA suppression, and nadir CD4+ counts).
Persistance of immune activation and high levels of inflamma-
tion have been identified as the underlying mechanisms inducing 
suboptimal immunological response to ART. We showed that 
NLRP3 expression is significantly increased in unstimulated or 
HIV-stimulated PBMCs of INRs as compared to patients who 
experienced complete immune recovery under ART. This result 
is of particular interest because, while there is ample evidence of 
inflammasome role during acute infection (19–22), there are no 
reports, to this date, on inflammasome expression during chronic 
infection. Importantly, we found that the condition of unsatisfac-
tory CD4+ T-cell recovery under ART was associated with a 
significantly increased expression of NLRP3 even after adjust-
ment for age and CD4+ T-cell nadir, which are known conditions 
able to influence immune recovery and immune activation in 
virologically suppressed patients. To characterize inflamma-
some expression in IRs and INRs, we stimulated PBMCs with 
LPS, which is known to be a potent activator of inflammasomes 
pathway. In LPS-stimulated PBMCs we observed that INRs were 
more responsive to LPS stimulation compared to IRs, suggesting a 
higher immune activation status, with an upregulation of NLRP3 
and caspase-1 gene expression. In addition, we also reported a 
significant increase of inflammasome-related cytokines, such 
as IL-1β and IL-18 that are directly linked to inflammasome 
activation.
Next, we verified if HIV could be able to activate inflam-
masomes even in the settings of chronic infection as this issue 
has not yet been clearly addressed by other studies. Pontillo et al. 
reported that HIV is able to induce NLRP3 expression upon 
infection, but that fails to do so in chronically activated cells from 
infected individuals (19). Interestingly, we observed that HIV was 
indeed less efficient in stimulating the inflammasome pathway 
compared to LPS; however, we could still detect an upregulation 
of NLRP3, IL-1β, and IL-18 in INRs compared to IRs suggest-
ing that inflammasome pathway is upregulated in these patients 
compared to IRs. Our results are apparently in contrast with 
pieces of evidence from a previous work by Nasi et al. who found 
that the expression of genes involved in inflammasome pathways 
did not significantly differ between HIV-infected patients under 
ART and healthy subjects (23). However, HIV-infected patients 
evaluated in that study had higher CD4+ T-cell count (about the 
range of normality) and inflammasome activation was analyzed 
only in basal conditions, whereas we found major differences 
after LPS- and HIV-stimulation between INR and IR patients.
Moreover, we found that INRs express significantly higher 
levels of caspase-1 either in unstimulated or LPS- or AT2-treated-
HIV-1BaL treated cells, even after adjustment for CD4+ T-cell 
nadir, thus suggesting a role of caspase-1-dependent pyroptosis 
in CD4+ T-cell death and probably in the lack of immune recov-
ery. In the age-adjusted analysis, the association between INRs 
and higher levels of caspase-1 was lost; however, our analysis was 
partly limited by the small sample size. This finding is consist-
ent with recent studies in which pyroptosis has been shown as a 
major player in CD4+ T lymphocyte loss contributing to immune 
activation in HIV infection. It has also been reported that this 
process would take place primarily in the lymph node, rather 
than in the blood. Indeed, even though quiescent blood CD4+ 
T cell support HIV entry and fusion, they are also highly resistant 
to pyroptotic cell death and this is probably due to their deeper 
state of cellular rest (13). Nevertheless, we were able to observe 
an upregulation of genes involved in inflammasome pathway, 
especially caspase-1, and this could be due to the fact that we 
analyzed PBMCs, which are a heterogeneous cell population 
compromising not only CD4+ T cells but other lymphocytes and 
monocytes too. Monocytes are known for constitutive caspase-1 
expression (24) and release of IL-1β upon TLR4 stimulation. We 
can hypothesize that t the higher expression levels of inflamma-
some components observed in INRs could depend on increased 
monocytes activation in INRs compared to IRs. Of note, the array 
data of LPS-stimulated PBMCs, showed a significant upregulation 
7Bandera et al. Inflammasome Immune-Recovery under ART
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of TLR4 in INRs compared to IRs. In agreement with reports from 
Muñoz-Arias et al., (13), we could not detect any differences in 
IFI16 expression in PBMCs from INRs and IRs, which is probably 
due to the resting condition of blood CD4+ T cells.
Recently microbial translocation has been considered one of 
the main drivers of immune activation during HIV infection and 
so we decided to evaluate this phenomenon in our patients. We 
wondered if the up-regulation of the inflammasome pathway 
observed in INRs could be dependent on increased levels of 
microbial translocation. Surprisingly, we could not detect any 
differences in plasma levels of LPS and sCD14 between INRs 
and IRs, indicating that microbial translocation is not the main 
driver of inflammasome and immune activation in our cohort. 
Consistent with our results are also recent reports by Tincati et al. 
and Stiksrud et  al. in which no differences in LPS and sCD14 
plasma levels could be detected between INRs and IRs (25, 26). 
It has been suggested that probably while microbial transloca-
tion markers have been shown to predict clinical outcome in 
untreated HIV infection, their use in ART-treated patients may 
not be as accurate (27).
In conclusion, it is tempting to speculate that higher inflamma-
some up-regulation observed in INRs may be due to residual HIV 
defective replication taking place in immune sanctuaries, which 
would lead to inflammation, immune activation and cell death. Of 
note, there have been reports showing that cell-to-cell transmis-
sion of HIV is not efficiently inhibited by ART and that it effectively 
triggers pyroptotic cell death of lymphoid-tissue-derived CD4+ 
T cells (11, 14), suggesting that depletion of CD4+ T cells would 
still take place in spite of suppressed viremia. In addition, it has 
been demonstrated that defective proviruses are able to transcribe 
novel protein-coding RNA species in HIV-infected patients on 
ART and with suppressed viremia (RNA levels <50 copies/ml) 
(28) and recent data presented at CROI 2017 demonstrated the 
production of HIV-1 proteins from these defective proviruses 
(29). These viral proteins produced even in the settings of sup-
pressed viremia could be sensed by inflammasomes, leading 
to higher rates of immune activation during chronic infection 
and possibly to lack of immune response in INRs. The higher 
inflammasome upregulation observed in INRs may depend on 
an increased number of monocytes in these patients. It is of par-
ticular interest considering that activation of innate immunity has 
been linked to morbidity and mortality in the setting of ART-
treated HIV infection (30, 31). Our data indicate that inflam-
masome and caspase-1 may be involved and play an important 
role in the lack of immunological response and higher immune 
activation status of INRs, however further investigations are nec-
essary in order to fully prove this hypothesis. We expect that new 
studies on the molecular pathways involved in inflammasome, 
and pyroptotic cell death will shed light on molecular markers and 
features of these processes that could then be investigated in INRs.
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